Core Viewpoint - Fangsheng Pharmaceutical (603998) announced that its wholly-owned subsidiary, Guangdong Fangsheng Jianmeng Pharmaceutical Co., Ltd., has received the Clinical Trial Approval Notice from the National Medical Products Administration for the development of the generic drug RuLuGoli Tablets, which is a GnRH receptor antagonist for the treatment of advanced prostate cancer in adults [1] Company Summary - The RuLuGoli Tablets have not yet been launched in China, and there are currently no original or generic products approved for sale in the country [1] - Other companies, such as Haibu Pharmaceutical and Lianhuan Pharmaceutical (600513), have also received clinical trial approvals and plan to conduct related clinical trials [1]

Core Viewpoint - Fangsheng Pharmaceutical's subsidiary has received approval for a clinical trial of a new drug aimed at treating advanced prostate cancer, indicating progress in its drug development pipeline [1] Group 1: Company Developments - Fangsheng Pharmaceutical announced on October 15 that its wholly-owned subsidiary, Fangsheng Jianmeng, has received the "Drug Clinical Trial Approval Notice" from the National Medical Products Administration for the drug RuLuGoli Tablets [1] - RuLuGoli Tablets are classified as gonadotropin-releasing hormone (GnRH) receptor antagonists, specifically designed for the treatment of adult advanced prostate cancer [1]